FARMAKOTERAPIYa BOLEZNI PARKINSONA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article considers general principles of pharmacotherapy of Parkinson's disease (PD). Based on Russian guidelines for the treatment of BP and international recommendations, the problems of choosing a drug for the treatment and correction of motor fluctuations and dyskinesias, autonomic and mental disorders are discussed. The role of new dosage form of dopamine receptor agonist pramipexole (Mirapex ER) in the treatment of PD is evaluated.

Full Text

Restricted Access

About the authors

O. S Levin

Email: neurolev@mail.ru

V. K Datieva

References

  1. Голубев В.Л., Левин Я.И., Вейн А.М. Болезнь Паркинсона и синдром паркинсонизма. М., 1999, 415 с.
  2. Левин О.С., Федорова Н.В. Болезнь Паркинсона. М., 2012. 352 с.
  3. Левин О.С., Смоленцева И.Г., Цэрэнсодном Б. Эффективность прамипексола при болезни Паркинсона (по данным открытого 12-месячного исследования) // Фарматека 2007. № 1. С. 28-34.
  4. Протокол ведения больных. Болезнь Паркинсона // Проблемы стандартизации в здравоохранении 2005. № 3. C. 74-166.
  5. Шток В.Н., Иванова-Смоленская И.А., Левин О.С. и др. Экстрапирамидные расстройства. М., 2002. 606 с.
  6. Barone P. Clinical strategies to prevent and delay motor complications. Neurology 2003; 61 (3): 12-6.
  7. Chwieduk C.M., Curran M.P. Pramipexole extended release in Parkinson's disease. CNS Drugs 2010; 24: 327-36.
  8. Horstinik M., Tolosa E., Bonucelli U., et al. Review of the therapeutic management of Parkinson's disease. Report of joint task force of EFNS and MDS-ES. Eur J Neurol 2006; 13: 11 70-85.
  9. Koller W.C., Tse W. Unmet medical needs in Parkinson's disease. Neurology 2004; 62: 17-22.
  10. Lees A.J. Drugs for Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 607-10.
  11. Miyasaki J.M., Martin W., Suchowersky O., et al. Practice parameter: Initiation of treatment for Parkinson disease: An evidence-based review. Neurology 2002; 58: 11-7.
  12. Miyasaki J.M., Shannon K., Voon V., et al. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Neurology 2006; 66: 996: 1002.
  13. Olanow C., Watts R., Koller W. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(5): 1-88.
  14. Pahwa R., Factor S.A., Lyons K.E., et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Neurology 2006; 66: 983-95.
  15. Rascol O., Goetz C., Koller W., et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-98.
  16. Stowe R., Ives N., Clarke C.E., et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD007166. doi: 10.1002/14651858. CD007166. pub2.
  17. Suchowersky O., Gronseth G., Perlmutter J., et al. Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Neurology 2006; 66. 976-82.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies